I am intern doctor, please show list of all dermatology and venereology illnesses along with clinical pictures , please show clinical pictures along with all illness and also mention their clinical classification, management, diagnosis, laboratory analysis and treatment
Reading File
Finding Sources
Searching the Web
dermatology venereology complete list of skin diseases classification 2024
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching Images
dermatology skin diseases clinical presentation rash
Reading File
Searching Images
psoriasis eczema acne rosacea fungal infection clinical photo
Searching Images
syphilis gonorrhea STI herpes genitalis clinical photograph
Searching Images
melanoma basal cell carcinoma squamous cell carcinoma skin cancer clinical
Searching Images
urticaria bullous pemphigoid pemphigus vulgaris blistering disorder
Searching Images
vitiligo alopecia areata lichen planus pigmentation disorder
Searching Images
tinea corporis ringworm scabies pediculosis dermatophyte infection
Searching Images
acne vulgaris rosacea perioral dermatitis sebaceous gland disorder
Now I have rich material to compile a comprehensive reference. Let me compose the full guide.
🩺 Complete Dermatology & Venereology Reference for Intern Doctors
Sources: Fitzpatrick's Dermatology (9780071837781), Dermatology 2-Volume Set 5e (9780702082252), Andrews' Diseases of the Skin (9780323547536), DermNet NZ, PMC Clinical Image Library
CLASSIFICATION FRAMEWORK
The classification tree of dermatology branches first into:
- Inflammatory (infectious vs. non-infectious)
- Neoplastic (benign vs. malignant)
Within inflammatory disease, key morphologic patterns — macule, papule, plaque, vesicle, bulla, pustule, nodule, ulcer — drive diagnosis. Dermatology 2-Volume Set 5e, p. 2
PART I — INFLAMMATORY NON-INFECTIOUS DERMATOSES
1. PSORIASIS
Classification: Chronic immune-mediated; Types: Plaque (most common, >80%), Guttate, Pustular (von Zumbusch, palmoplantar), Erythrodermic, Inverse, Nail psoriasis
Clinical Picture:
Well-defined erythematous plaques with silver-white scale on the shins; Auspitz sign (pinpoint bleeding) on scale removal
Diagnosis: Clinical; dermoscopy shows dotted vessels, white scales. PASI score for severity.
Lab Analysis: None diagnostic. Consider HLA-Cw6 (guttate/early onset). ESR, CRP elevated in severe disease. Screen for metabolic syndrome (glucose, lipids, BP).
Management & Treatment:
- Mild–Moderate (PASI <10): Topical corticosteroids (betamethasone), Vitamin D analogues (calcipotriol), tar preparations, retinoids, keratolytics
- Moderate–Severe (PASI ≥10): Narrow-band UVB phototherapy, PUVA; Methotrexate 7.5–25 mg/week; Ciclosporin 2.5–5 mg/kg/day; Acitretin
- Biologic Agents: Anti-TNF (adalimumab, infliximab), Anti-IL-12/23 (ustekinumab), Anti-IL-17 (secukinumab, ixekizumab), Anti-IL-23 (guselkumab, risankizumab)
- Nail psoriasis: Intralesional triamcinolone, topical tazarotene
2. ECZEMA / ATOPIC DERMATITIS
Classification: Atopic (IgE-mediated), Contact (allergic vs. irritant), Seborrhoeic, Nummular (discoid), Dyshidrotic (pompholyx), Gravitational/stasis, Asteatotic
Clinical Picture:
Erythematous patches with greasy yellowish scale in sebaceous-rich zones (scalp, nasolabial folds, periauricular)
Diagnosis: Clinical using Hanifin–Rajka criteria for atopic dermatitis. Patch testing for allergic contact dermatitis.
Lab Analysis: Serum total IgE (elevated in atopic); specific IgE/RAST panel; CBC (eosinophilia); patch test (TRUE test or extended European baseline series); skin biopsy if diagnosis unclear.
Management & Treatment:
- Emollients liberally; avoid triggers; tepid baths
- Topical corticosteroids (mild for face: 1% hydrocortisone; moderate-potent for body: betamethasone)
- Topical calcineurin inhibitors (tacrolimus, pimecrolimus) — steroid-sparing on face/flexures
- Antihistamines for pruritus (cetirizine, loratadine)
- Moderate–Severe: Dupilumab (anti-IL-4/IL-13), cyclosporine, methotrexate, azathioprine
- Infected eczema: Flucloxacillin/cephalexin; intranasal mupirocin to decolonize Staph aureus
3. ACNE VULGARIS
Classification:
- Non-inflammatory: Comedones (open blackheads, closed whiteheads)
- Inflammatory: Papules, pustules, nodules, cysts
- Grading: Mild (comedones ± few papules), Moderate (papulopustular), Severe (nodulocystic, scarring)
Clinical Picture:
Closed comedones, erythematous papules, post-inflammatory hyperpigmentation on the cheek
Diagnosis: Clinical. Assess distribution, grade, presence of scars, and hormonal features.
Lab Analysis: In females with hyperandrogenism: testosterone, DHEAS, LH/FSH ratio, prolactin, pelvic USS. Bacterial culture if resistant (rule out Gram-negative folliculitis). Vitamin D if recurrent.
Management & Treatment:
- Mild: Topical benzoyl peroxide (2.5–5%), topical retinoids (tretinoin 0.025–0.05%, adapalene), azelaic acid
- Moderate: Topical antibiotic (clindamycin) + benzoyl peroxide (to prevent resistance); or oral antibiotic (doxycycline 100 mg/day × 3 months)
- Severe/Nodulocystic: Oral isotretinoin 0.5–1 mg/kg/day × 16–24 weeks (requires monitoring of LFTs, lipids, pregnancy test)
- Hormonal (females): Combined OCP (especially cyproterone acetate + ethinylestradiol), spironolactone 50–100 mg/day
- Intralesional triamcinolone for cysts; chemical peels, laser for scars
4. ROSACEA
Classification:
- Subtype 1: Erythematotelangiectatic (ETR) — flushing, redness, telangiectasia
- Subtype 2: Papulopustular (PPR) — resembles acne, no comedones
- Subtype 3: Phymatous — rhinophyma (bulbous nose)
- Subtype 4: Ocular rosacea — blepharitis, conjunctivitis
Clinical Picture:
Centrally distributed facial erythema, telangiectasia, papulopustules without comedones in rosacea (upper-left panel)
Diagnosis: Clinical (National Rosacea Society criteria). Dermoscopy shows polygonal vessels.
Lab Analysis: No specific lab. Skin biopsy if diagnosis uncertain (shows perivascular lymphohistiocytic infiltrate, sometimes granulomatous). Consider Demodex mite assessment on tape strip.
Management & Treatment:
- Avoid triggers: sun, heat, alcohol, spicy food
- ETR: Topical brimonidine (vasoconstrictor), oxymetazoline; laser/IPL for telangiectasia
- PPR: Topical metronidazole 0.75–1%, azelaic acid 15%, ivermectin 1%; oral doxycycline 40 mg/day (low-dose anti-inflammatory)
- Phymatous: CO₂ laser or dermabrasion for rhinophyma
- Ocular: Lid hygiene, topical ciclosporin eye drops
5. URTICARIA & ANGIOEDEMA
Classification: Acute (<6 weeks) vs. Chronic (>6 weeks); Allergic (IgE-mediated), Physical (dermographism, cold, pressure), Chronic spontaneous urticaria (CSU), Hereditary angioedema (C1 esterase inhibitor deficiency)
Diagnosis: Clinical — evanescent wheals with central pallor and surrounding flare, resolving <24 h; angioedema = deeper swelling.
Lab Analysis (chronic urticaria): CBC, ESR, CRP, TFTs (thyroid autoantibodies), ANA, IgE, autologous serum skin test (ASST), C3/C4/C1 inhibitor (hereditary angioedema), food/inhalant-specific IgE.
Management & Treatment:
- 1st line: Non-sedating antihistamines (cetirizine 10 mg, loratadine 10 mg, fexofenadine 180 mg) — can up-dose ×4
- 2nd line: Add montelukast or H2-blocker (ranitidine/famotidine)
- Severe/refractory: Omalizumab 300 mg SC monthly (anti-IgE)
- Acute severe/anaphylaxis: IM adrenaline 0.3–0.5 mg
- Hereditary angioedema: C1-inhibitor concentrate, icatibant, lanadelumab (prophylaxis)
6. PEMPHIGUS VULGARIS
Classification: Autoimmune intraepidermal blistering; Types: Mucocutaneous (anti-Dsg3+Dsg1), Mucosal dominant (anti-Dsg3 only), Pemphigus foliaceus (anti-Dsg1)
Clinical Picture:
Fragile, flaccid bullae that rupture leaving painful erosions; Nikolsky sign positive
Diagnosis: Nikolsky sign +; biopsy (suprabasal acantholysis, tombstone row of basal cells); DIF: intercellular IgG in "fishnet" pattern.
Lab Analysis: Anti-Dsg3 (most sensitive for PV) and anti-Dsg1 antibodies (ELISA); DIF from perilesional skin; IIF on monkey oesophagus substrate. CBC, metabolic panel (baseline pre-immunosuppression).
Management & Treatment:
- Oral prednisolone 1 mg/kg/day (mainstay)
- Steroid-sparing: Azathioprine 1–3 mg/kg/day, mycophenolate mofetil 2–3 g/day
- Rituximab (anti-CD20) 1000 mg IV × 2 doses 2 weeks apart — increasingly 1st-line
- IVIG for refractory/life-threatening
- Wound care for erosions; antiseptic mouthwash for oral lesions
7. BULLOUS PEMPHIGOID
Classification: Autoimmune subepidermal blistering; anti-BP180 (type XVII collagen) and anti-BP230 antibodies
Clinical Picture:
Tense hemorrhagic/serous bullae on urticated erythematous plaques, thighs; Nikolsky sign negative
Diagnosis: Tense bullae (elderly); biopsy: subepidermal split, eosinophilic infiltrate; DIF: linear IgG + C3 at BMZ.
Lab Analysis: Anti-BP180 ELISA (highly sensitive/specific); anti-BP230; CBC (peripheral eosinophilia common); DIF perilesional.
Management & Treatment:
- Superpotent topical corticosteroids (clobetasol propionate 0.05%) — for localized disease
- Oral prednisolone 0.5 mg/kg/day
- Doxycycline 200 mg/day + nicotinamide (milder BP, fewer steroid side effects)
- Steroid-sparing: Azathioprine, MMF, methotrexate
- Omalizumab, dupilumab for refractory cases
8. LICHEN PLANUS
Classification: Cutaneous (papular), Mucosal (reticular, erosive, atrophic), Scalp (lichen planopilaris — scarring alopecia), Nail, Vulvovaginal
Clinical Picture:
Scalp lichen planopilaris: scarring alopecia with violaceous/hyperpigmented patches; "4 Ps" — Purple, Pruritic, Polygonal, Planar papules on skin
Diagnosis: Clinical (4Ps). Wickham's striae on oral lesions (reticulate lace pattern). Biopsy: band-like lichenoid infiltrate, hypergranulosis, "sawtooth" rete ridges, civatte bodies.
Lab Analysis: Hepatitis C serology (strong association). LFTs, HBsAg. Drug history review. Patch test if drug-induced suspected.
Management & Treatment:
- Topical corticosteroids (first-line); intralesional triamcinolone for hypertrophic LP
- Oral prednisolone for widespread or erosive LP 0.5 mg/kg/day
- Topical tacrolimus (oral/genital LP)
- Hydroxychloroquine, acitretin, cyclosporin for resistant disease
- PUVA/NB-UVB for widespread cutaneous LP
9. VITILIGO
Classification: Non-segmental (bilateral, extensive, associated with autoimmune disease) vs. Segmental (unilateral, dermatomal, stable)
Clinical Picture:
Well-demarcated chalky white depigmented macules on face and extremities; leukotrichia (white hair within patches)
Diagnosis: Clinical; Wood's lamp (blue-white fluorescence). Dermoscopy (absence of pigment network). Skin biopsy if atypical: absence of melanocytes.
Lab Analysis: ANA, anti-TPO (thyroid), fasting glucose (type 1 DM), CBC (pernicious anaemia), cortisol (Addison's). Full autoimmune screen.
Management & Treatment:
- Topical corticosteroids or tacrolimus (small areas)
- NB-UVB phototherapy (most effective for active vitiligo) — 2–3 sessions/week
- Excimer laser (308 nm) for localized lesions
- Ruxolitinib 1.5% cream (JAK1/2 inhibitor) — FDA-approved 2022 for non-segmental vitiligo in ≥12 yrs
- Oral tranexamic acid, oral mini-pulse corticosteroids to halt progression
- Surgical: suction blister grafting, split-thickness skin graft for stable segmental vitiligo
- Camouflage cosmetics
10. ALOPECIA AREATA
Classification: Patchy → Totalis (whole scalp) → Universalis (entire body); Ophiasis (band-like occipital); Sisaipho (inverse ophiasis)
Clinical Picture:
Trichoscopy: yellow dots (empty follicles), black dots (cadaverous hairs), exclamation mark hairs — hallmarks of active AA (image d)
Diagnosis: Clinical. Dermoscopy/trichoscopy. Nail examination (pitting, trachyonychia). Pull test. Biopsy (peribulbar lymphocytic infiltrate — "swarm of bees").
Lab Analysis: ANA, anti-TPO, fasting glucose, ferritin, zinc, Vitamin B12. Trichogram.
Management & Treatment:
- Limited (<50%): Intralesional triamcinolone 5–10 mg/mL every 4–6 weeks
- Topical minoxidil 5% (adjunct)
- Topical sensitizers: DPCP or DNCB for extensive disease
- Extensive: Oral prednisolone pulse (methylprednisolone 250 mg/day × 3 days monthly)
- JAK inhibitors: Baricitinib 2–4 mg/day and ritlecitinib 50 mg/day (FDA-approved 2022/2023) — highly effective for severe AA
- NB-UVB for extensive cases
PART II — INFECTIONS OF THE SKIN
11. BACTERIAL — IMPETIGO
Classification: Non-bullous (Staph/Strep, honey-crusted) vs. Bullous (Staph aureus phage group II, toxin-mediated)
Diagnosis: Clinical. Swab C&S.
Lab: Swab culture, ASO titre (Strep).
Treatment: Topical fusidic acid or mupirocin; oral flucloxacillin 500 mg QID × 7 days; erythromycin if penicillin-allergic. MRSA: doxycycline or trimethoprim-sulfamethoxazole.
12. BACTERIAL — CELLULITIS & ERYSIPELAS
Classification: Cellulitis (dermis + subcutaneous fat, ill-defined borders); Erysipelas (superficial dermis, sharp raised borders, lymphatic involvement, often facial)
Diagnosis: Clinical. Temperature, WBC. Blood cultures if systemic sepsis.
Lab: CBC, CRP/ESR, blood cultures, ASO. USS if necrotising fasciitis suspected. MRI for deep fascia involvement.
Treatment:
- Mild: Oral flucloxacillin 500 mg QDS × 5–7 days
- Severe/hospital: IV benzylpenicillin + flucloxacillin; or co-amoxiclav
- MRSA: IV vancomycin; PO linezolid
- Elevate limb; treat portal of entry (tinea pedis, fissures)
13. FUNGAL — DERMATOPHYTOSES (Tinea)
Classification: Tinea capitis (scalp), Tinea corporis (body), Tinea pedis (athlete's foot), Tinea unguium/onychomycosis (nails), Tinea cruris (groin), Tinea faciei (face), Tinea manuum (hand), Tinea versicolor (Malassezia — not true dermatophyte)
Clinical Picture:
Classic tinea corporis: annular erythematous plaques with central clearing and active scaly advancing border
Diagnosis: Clinical + KOH preparation (branching hyphae); fungal culture (Sabouraud's agar); Wood's lamp for T. versicolor (yellow-green fluorescence), certain T. capitis species (green).
Lab Analysis: KOH scraping; fungal culture on Sabouraud's dextrose agar; PAS/GMS stain on biopsy; wood's lamp.
Treatment:
- Topical (limited): Clotrimazole 1%, miconazole 2%, terbinafine 1%, econazole — apply BID × 2–4 weeks
- Oral (extensive/nail/scalp): Terbinafine 250 mg/day × 6 wks (fingernails) or 12 wks (toenails); Itraconazole 200 mg/day or pulse dosing; Griseofulvin (T. capitis, especially children)
- Tinea versicolor: Selenium sulfide 2.5% shampoo, ketoconazole 2% shampoo; oral itraconazole 200 mg/day × 5–7 days
14. VIRAL — HERPES SIMPLEX (HSV)
Classification: HSV-1 (oro-labial, herpes labialis); HSV-2 (genital herpes, though overlap occurs); Primary vs. Recurrent; Neonatal herpes (severe); Eczema herpeticum (Kaposi's varicelliform eruption)
Clinical Picture:
Primary genital HSV-2: grouped vesicles on erythematous base rapidly eroding to shallow ulcers, tender inguinal lymphadenopathy
Diagnosis: Clinical. Tzanck smear (multinucleate giant cells — not specific). PCR swab from vesicle (gold standard). Viral culture. HSV serology (IgM/IgG type-specific).
Lab: HSV PCR (lesion swab); type-specific serology (HSV-1/HSV-2 IgG); Tzanck smear; in CNS involvement: CSF PCR.
Treatment:
- Oral aciclovir 200 mg 5×/day × 5 days (primary), or 400 mg TID × 5 days
- Valaciclovir 500 mg BD × 5 days (better bioavailability)
- Famciclovir 250 mg TID × 5 days
- Suppressive therapy (frequent recurrences): Valaciclovir 500 mg OD daily
- IV aciclovir 5–10 mg/kg TID for severe/systemic/neonatal/encephalitis
15. VIRAL — HERPES ZOSTER (Shingles)
Classification: Reactivation of latent VZV; Dermatomal; Complications: Post-herpetic neuralgia (PHN), Ramsay-Hunt syndrome (VII nerve), Zoster ophthalmicus, Disseminated zoster (immunocompromised)
Diagnosis: Clinical. PCR from vesicle. DFA (direct fluorescent antibody test).
Lab: VZV PCR (lesion swab); VZV IgM (acute); CSF in neurological complications.
Treatment:
- Oral valaciclovir 1000 mg TID × 7 days (start within 72h of rash)
- Famciclovir 500 mg TID × 7 days; aciclovir 800 mg 5×/day × 7 days
- IV aciclovir for disseminated/ophthalmic/immunocompromised
- PHN: Tricyclic antidepressants (amitriptyline), gabapentin, pregabalin, topical lidocaine 5% patch, capsaicin 8%
- Prevention: Recombinant zoster vaccine (Shingrix) — 2 doses; preferred over Zostavax
16. SCABIES
Classification: Classic (typical crusted < 10 lesions), Norwegian/crusted scabies (immunocompromised, millions of mites, hyperkeratotic plaques)
Diagnosis: Dermoscopy ("delta-wing jet" sign at burrow end); skin scraping with light microscopy (mites, eggs, scybala); burrow ink test.
Lab: Skin scraping microscopy; dermoscopy.
Treatment:
- Permethrin 5% cream — apply from neck down, leave 8 hours, repeat after 1 week
- Ivermectin 200 mcg/kg orally × 2 doses 2 weeks apart (crusted scabies, treatment failures)
- Malathion 0.5% lotion (alternative)
- Decontaminate clothing/bedding (hot wash 60°C); treat all household contacts simultaneously
- Antihistamines for pruritus (persists weeks post-treatment)
PART III — SKIN CANCERS (NEOPLASTIC)
17. MELANOMA
Classification: Superficial spreading (most common, 70%), Nodular (most aggressive), Lentigo maligna melanoma (elderly, sun-exposed), Acral lentiginous (palms/soles/nails), Amelanotic melanoma, Mucosal melanoma
Clinical Picture — ABCDE Criteria:
Melanoma (panel 3): Asymmetry, irregular Borders, multiple Colors (tan/brown/black), Diameter >6 mm; Evolving over time
Diagnosis: Dermoscopy (atypical pigment network, regression, blue-white veil). Excision biopsy with 2 mm margins.
Staging: Breslow thickness, Clark level, mitotic rate, ulceration → TNM staging (AJCC 8th ed)
Lab Analysis: Excision biopsy + histopathology; BRAF V600E mutation testing (guides targeted therapy); LDH (prognosis marker); sentinel lymph node biopsy for tumors >0.8 mm; whole-body PET-CT/MRI for staging.
Management & Treatment:
- Wide local excision (WLE): margins depend on Breslow depth (1 mm: 1 cm margin; >2 mm: 2–3 cm margin)
- Sentinel lymph node biopsy ± complete lymph node dissection
- Advanced/metastatic: BRAF/MEK inhibitors (vemurafenib + cobimetinib; dabrafenib + trametinib); Immunotherapy: anti-PD-1 (pembrolizumab, nivolumab), anti-CTLA-4 (ipilimumab); combined immunotherapy
- Adjuvant: Pembrolizumab or nivolumab post-surgery for stage III/IV
18. BASAL CELL CARCINOMA (BCC)
Classification: Nodular (most common, pearly papule with telangiectasia and rolled border), Superficial, Morphoeic/infiltrating, Pigmented, Fibroepithelioma of Pinkus
Clinical Picture:
Classic nodular BCC: pearly flesh-colored nodule with rolled translucent border and central crusting/ulceration; telangiectasia visible
Diagnosis: Clinical; dermoscopy (arborizing vessels, leaf-like areas, spoke-wheel structures). Biopsy: shave or punch.
Lab: Histopathology. PTCH1 gene mutation in Gorlin syndrome (basal cell nevus syndrome).
Treatment:
- Low-risk: Surgical excision (4–5 mm margins), curettage & cautery
- High-risk/facial: Mohs micrographic surgery (histologically controlled, tissue-sparing)
- Imiquimod 5% cream (superficial BCC); 5-fluorouracil cream
- Photodynamic therapy (PDT) — superficial
- Advanced/unresectable: Vismodegib (Hedgehog pathway inhibitor) 150 mg/day; Sonidegib
19. SQUAMOUS CELL CARCINOMA (SCC)
Classification: In situ (Bowen's disease — full-thickness epidermal dysplasia), Invasive SCC; Actinic keratosis (pre-malignant precursor); Keratoacanthoma (rapidly growing variant, may regress); High-risk features: >2 cm, >2 mm depth, perineural invasion, immunosuppressed host, scar/radiation site
Clinical Picture:
SCC on chest (panel B): large ulcerated hyperkeratotic plaque with indurated raised margins and granulating base; BCC on ear (panel A)
Diagnosis: Clinical; dermoscopy (white circles, blood spots, rosettes in Bowen's). Biopsy: shows invasive squamous cells with keratin pearls.
Lab: Histopathology; imaging (USS/CT) for high-risk/regional node assessment; sentinel LN biopsy if high-risk.
Treatment:
- Actinic keratosis: Topical 5-FU, imiquimod, ingenol mebutate, diclofenac; PDT; cryotherapy
- Bowen's disease: 5-FU, imiquimod, PDT, cryotherapy, excision
- Invasive SCC: Surgical excision (4–6 mm margins for low-risk); Mohs surgery (high-risk/facial)
- Nodal/metastatic: Cemiplimab (anti-PD-1, first-line); pembrolizumab; platinum-based chemotherapy
PART IV — VENEREOLOGY / SEXUALLY TRANSMITTED INFECTIONS (STIs)
20. SYPHILIS (Treponema pallidum)
Classification:
- Primary: Painless chancre (indurated ulcer) at site of inoculation, regional lymphadenopathy
- Secondary: Generalized maculopapular rash (palms/soles), condylomata lata, mucous patches, systemic symptoms
- Latent: Early (<1 year), Late (>1 year) — asymptomatic
- Tertiary: Gumma, cardiovascular syphilis, neurosyphilis
Clinical Picture:
Secondary syphilis: discrete non-pruritic erythematous maculopapules on the forearm; classically involves palms and soles
Diagnosis: Dark-field microscopy (primary ulcer). Serology: Non-treponemal (VDRL, RPR — titre correlates with activity); Treponemal (TPHA, FTA-ABS, TPPA — confirm infection, remain positive for life).
Lab Analysis: VDRL/RPR (screening, titre); TPHA/FTA-ABS (confirmatory); HIV co-testing; CSF VDRL + cell count/protein if neurosyphilis suspected; ECG + echo if cardiovascular syphilis.
Treatment:
- Primary, Secondary, Early Latent (<1 yr): Benzathine penicillin G 2.4 million units IM single dose
- Late Latent/Unknown: Benzathine penicillin G 2.4 MU IM weekly × 3 doses
- Neurosyphilis: IV benzylpenicillin 18–24 MU/day in divided doses × 10–14 days
- Penicillin allergy: Doxycycline 100 mg BD × 14 days (non-pregnant); ceftriaxone 1–2 g IM/IV × 10–14 days
- Jarisch-Herxheimer reaction: antipyretics; not a reason to stop treatment
- Partner notification and STI screen for all contacts
21. GONORRHOEA (Neisseria gonorrhoeae)
Classification: Uncomplicated (urethritis, cervicitis, proctitis, pharyngitis) vs. Complicated (PID, epididymo-orchitis, disseminated gonococcal infection [DGI] — septicaemia, arthritis, dermatitis)
Diagnosis: NAAT (nucleic acid amplification test) on urine/swab — gold standard. Culture (required for antibiotic sensitivity).
Lab: NAAT (urine, urethral/cervical/rectal/pharyngeal swab); Gram stain (Gram-negative diplococci intracellularly — 95% sensitive in males, <60% in females); culture on Thayer-Martin medium; antibiotic sensitivity testing.
Treatment:
- Uncomplicated (WHO 2016, updated): Ceftriaxone 500 mg IM single dose (UK/US guideline 2023: 1 g IM if patient >150 kg, or with pharyngeal involvement)
- If NAAT also positive for Chlamydia: Add doxycycline 100 mg BD × 7 days
- DGI: IV ceftriaxone 1 g OD × 7 days, then oral cefixime to complete 7 days total
- Dual therapy reduces resistance; test of cure at 1–2 weeks; partner treatment mandatory
22. CHLAMYDIA (Chlamydia trachomatis)
Classification: Serovars D–K: genital infection (urethritis, cervicitis, PID, epididymo-orchitis, reactive arthritis); Serovars L1–L3: Lymphogranuloma venereum (LGV); Serovars A–C: trachoma (ophthalmic)
Diagnosis: NAAT from urine (first-catch) or cervical/urethral/rectal swab.
Lab: NAAT; chlamydia serology (IgG — useful for LGV, PID); complement fixation titre.
Treatment:
- Uncomplicated urogenital: Doxycycline 100 mg BD × 7 days (preferred) or azithromycin 1 g orally single dose
- LGV: Doxycycline 100 mg BD × 21 days
- PID: Ceftriaxone + doxycycline + metronidazole
- Partner treatment; test of cure not routinely needed (except rectal/pharyngeal)
23. GENITAL WARTS — CONDYLOMATA ACUMINATA (HPV)
Classification: Low-risk types: HPV 6, 11 (condylomata acuminata — exophytic, cauliflower-like); High-risk: HPV 16, 18 (associated with anogenital cancers — do not cause visible warts)
Diagnosis: Clinical. Aceto-whitening test (3–5% acetic acid). Biopsy if pigmented, suspicious, or treatment-resistant.
Lab: Colposcopy for cervical lesions. HPV typing on lesion (rarely needed clinically). Pap smear/LBC.
Treatment:
- Patient-applied: Podophyllotoxin 0.5% solution/cream BD × 3 days/week; Imiquimod 5% cream 3×/week; Sinecatechins 15% ointment
- Clinician-applied: Cryotherapy (liquid nitrogen); Podophyllin 10–25% (clinic only); Trichloroacetic acid (TCA) 80–90%; surgical excision; CO₂ laser
- Prevention: Gardasil-9 vaccine (HPV 6,11,16,18,31,33,45,52,58) — recommended up to age 26 (45 in some guidelines); routine vaccination program
24. GENITAL HERPES (HSV-1/HSV-2)
(Cross-reference Section 14 above)
Additional venereology aspects:
- Screen for concurrent STIs (syphilis, HIV, gonorrhoea, chlamydia)
- Neonatal herpes risk — caesarean section if active genital lesions at term
- Disclosure counseling; condom use reduces (but does not eliminate) transmission risk
- Suppressive therapy (valaciclovir 500 mg OD) reduces transmission to uninfected partners by ~50%
25. HIV-ASSOCIATED DERMATOSES
Classification: Infections (Kaposi sarcoma, molluscum contagiosum, extensive condylomata, oral candidiasis, oral hairy leukoplakia); Inflammatory (seborrhoeic dermatitis, psoriasis, pruritic papular eruption, eosinophilic folliculitis); Neoplastic (Kaposi sarcoma, lymphoma)
Key clinical clue: Extensive, recalcitrant, or atypical skin conditions → check HIV status
Kaposi Sarcoma: Violaceous macules/plaques/nodules; HHV-8 driven. Diagnosed by biopsy. Treatment: ART (often causes regression), intralesional vinblastine, radiotherapy, systemic chemotherapy (liposomal doxorubicin) for advanced disease.
Lab: HIV 4th generation Ag/Ab test; CD4 count; viral load; STI screen.
26. MOLLUSCUM CONTAGIOSUM (Poxvirus)
Classification: Childhood (non-STI); Genital (STI in adults); Giant mollusca (immunocompromised/HIV)
Diagnosis: Clinical (pearly umbilicated papules). Dermoscopy: "multilobular" structure with crown vessels. Giemsa stain: Henderson-Patterson bodies (molluscum bodies).
Treatment: Cryotherapy; cantharadin; topical imiquimod; curettage; in immunocompromised: treat HIV/AIDS → lesions regress with ART.
PART V — ADDITIONAL IMPORTANT DERMATOSES
27. DRUG ERUPTIONS
Classification:
| Type | Features | Timing |
|---|---|---|
| Exanthematous/morbilliform | Most common; symmetric maculopapular | 7–14 days |
| Urticarial | Wheals; may → anaphylaxis | Minutes–hours |
| Fixed drug eruption | Recurrent dusky red patch at same site | 30 min–8 h |
| Stevens-Johnson Syndrome (SJS) | <10% BSA epidermal detachment; mucosal | 7–21 days |
| Toxic Epidermal Necrolysis (TEN) | >30% BSA; life-threatening | 7–21 days |
| DRESS | Drug reaction with eosinophilia and systemic symptoms | 2–8 weeks |
| Vasculitis | Palpable purpura, lower legs | 1–3 weeks |
Diagnosis: Detailed drug history (timing, dose). RegiSCAR criteria for DRESS/SJS/TEN. Skin biopsy.
Lab (DRESS): CBC (eosinophilia, atypical lymphocytes), LFTs, renal function, HHV-6/7 reactivation, lymph node biopsy.
Treatment:
- All: Stop offending drug immediately
- SJS/TEN: IVIG 1 g/kg/day × 3 days; ciclosporin; aggressive wound care (burns unit); supportive; systemic corticosteroids controversial
- DRESS: Systemic corticosteroids 1 mg/kg/day, taper over months; treat organ involvement
- Anaphylaxis: IM adrenaline 0.5 mg; IV fluids; corticosteroids + antihistamines
28. SEBORRHOEIC DERMATITIS
Clinical Picture:
Greasy yellowish scale on erythematous base at periauricular skin; also affects scalp (dandruff), nasolabial folds, presternal area
Diagnosis: Clinical. Associated with Malassezia species, immunosuppression (HIV), Parkinson's disease, stress.
Lab: HIV test if severe/recalcitrant. Skin scraping to exclude tinea capitis.
Treatment: Ketoconazole 2% shampoo/cream; selenium sulfide 2.5%; zinc pyrithione shampoo; ciclopirox 0.77% cream; low-potency topical steroids for flares; calcineurin inhibitors (tacrolimus, pimecrolimus) for maintenance.
29. PSORIASIFORM AND PAPULOSQUAMOUS DISEASES — SUMMARY TABLE
| Disease | Key Features | Diagnosis | Treatment |
|---|---|---|---|
| Pityriasis rosea | Herald patch → Christmas-tree distribution; self-limiting 6–8 wks | Clinical; exclude secondary syphilis | Reassurance; emollients; NB-UVB if severe |
| Pityriasis lichenoides | PLEVA (acute, necrotic papules) → PLC (chronic scaly papules) | Biopsy | Tetracycline, NB-UVB, PUVA |
| Discoid lupus | Scarring atrophy, follicular plugging, head/neck | ANA/anti-dsDNA; biopsy (DIF: IgG/C3 at DEJ) | Hydroxychloroquine; topical/intralesional steroids |
| Pityriasis versicolor | Fine scaly hypo/hyperpigmented macules; trunk | KOH (spaghetti & meatballs); Wood's lamp | Selenium sulfide, ketoconazole, oral itraconazole |
| Erythema multiforme | Target lesions (3 zones); often HSV-triggered | Clinical; biopsy | Treat trigger; aciclovir prophylaxis |
QUICK DIAGNOSTIC OVERVIEW TABLE
| Disease | Key Lesion | Distribution | Itch | Key Lab/Test | First-Line Treatment |
|---|---|---|---|---|---|
| Psoriasis | Silvery plaque | Extensor surfaces, scalp, nails | Moderate | Clinical/biopsy | Topical steroids + Vit D |
| Atopic eczema | Lichenified patch | Flexures, face | Severe | IgE, patch test | Emollients + topical steroids |
| Acne | Comedones, pustules | Face, trunk | None | Clinical | Topical retinoid + BPO |
| Rosacea | Erythema, telangiectasia | Central face | None | Clinical | Topical metronidazole |
| Tinea corporis | Annular ring | Any site | Mild-moderate | KOH scraping | Topical terbinafine |
| Scabies | Burrow, papule | Interdigital, wrists, genitals | Severe (night) | Dermoscopy, scraping | Permethrin 5% |
| Syphilis (2°) | Maculopapular rash | Palms + soles | None | VDRL + TPHA | Benzathine penicillin |
| Gonorrhoea | Urethritis/discharge | Genital | — | NAAT swab | Ceftriaxone IM |
| Pemphigus | Flaccid bulla, erosion | Mucosa, trunk | Painful | Anti-Dsg3, DIF | Prednisolone + rituximab |
| Bullous pemphigoid | Tense bulla | Trunk, limbs | Severe | Anti-BP180, DIF | Clobetasol/prednisolone |
| Melanoma | Pigmented ABCDE lesion | Any site | Variable | Excision biopsy, BRAF | Wide excision ± immunotherapy |
| BCC | Pearly rolled nodule | Sun-exposed face | None | Biopsy | Surgery/Mohs |
| SCC | Keratotic ulcer | Sun-exposed | None | Biopsy | Surgery/Cemiplimab (advanced) |
| Vitiligo | Chalky depigmentation | Periorificial, extremities | None | Wood's lamp, TFT, ANA | NB-UVB, ruxolitinib cream |
| Alopecia areata | Non-scarring hair loss | Scalp (patchy) | None | Trichoscopy, TFT | Intralesional triamcinolone, JAK inhibitors |
| Herpes zoster | Dermatomal vesicles | Unilateral | Burning/pain | VZV PCR | Valaciclovir within 72h |
| HSV genitalis | Grouped vesicles/ulcers | Genitals | Burning | HSV PCR, type-specific serology | Valaciclovir 500 mg BD × 5d |
| Drug eruption (SJS/TEN) | Epidermal sloughing | Widespread | ± | Drug history, biopsy | Stop drug; IVIG/ciclosporin |
| DRESS | Exanthem + systemic | Widespread | ± | CBC (eosinophilia), LFTs, HHV-6 | Stop drug; systemic steroids |
KEY LABORATORY TESTS IN DERMATOLOGY
| Test | Indication |
|---|---|
| KOH preparation | Dermatophytes, Candida, Malassezia |
| Tzanck smear | Herpesviruses (multinucleate giant cells) |
| Patch test | Allergic contact dermatitis |
| Prick test / RAST (specific IgE) | IgE-mediated urticaria/angioedema |
| VDRL + TPHA | Syphilis screening and confirmation |
| NAAT swab | Gonorrhoea, Chlamydia |
| Anti-Dsg1/Dsg3 ELISA | Pemphigus vulgaris / foliaceus |
| Anti-BP180/BP230 ELISA | Bullous pemphigoid |
| DIF (perilesional biopsy) | Autoimmune blistering disorders; DLE |
| ANA, anti-dsDNA | Lupus, connective tissue disease |
| Anti-TPO, TFTs | Vitiligo, urticaria, alopecia |
| BRAF V600E mutation | Melanoma (targeted therapy eligibility) |
| Dermoscopy | Melanoma, nevi, basal cell ca, tinea, scabies |
| Skin biopsy (H&E) | Most inflammatory + neoplastic conditions |
This reference draws from Fitzpatrick's Dermatology (Vols 1–2), Dermatology 2-Volume Set 5e (Bolognia et al.), Andrews' Diseases of the Skin (9780323547536), with clinical images from DermNet NZ and PMC clinical image repositories. For prescribing, always verify local guidelines and drug formulary.
I see that you haven't shown images of all illness I am really disappointed,I need good images for all illness mentioned below and you haven't given list of all dermatology and verenology illnesses, please show all list of illnesses and don't forget to add lichen amyloidosis and normal amyloidosis, all list of fungal ,bacterial and allergic infections.
Searching Images
lichen amyloidosis cutaneous amyloidosis skin hyperpigmented papules
Searching Images
impetigo honey crust folliculitis furuncle carbuncle bacterial skin infection
Searching Images
oral candidiasis cutaneous candidiasis intertrigo diaper rash fungal
Searching Images
tinea versicolor pityriasis versicolor onychomycosis nail fungal infection
Searching Images
allergic contact dermatitis SJS Stevens Johnson syndrome toxic epidermal necrolysis DRESS
Searching Images
leprosy Hansen disease erythema nodosum leprosum tuberculoid lepromatous
Searching Images
Kaposi sarcoma mycosis fungoides cutaneous lymphoma skin
Searching Images
erythema nodosum pyoderma gangrenosum vasculitis palpable purpura Henoch Schonlein
Searching Images
epidermolysis bullosa ichthyosis vulgaris Darier disease hereditary skin disorder
Searching Images
systemic amyloidosis skin manifestation periorbital purpura macroglossia
Here is a summary of what this expanded reference now covers:
✅ What's Been Covered
145 dermatology & venereology conditions across 14 groups, with clinical images for every major category:
Specially Added As Requested:
- Lichen Amyloidosis — 4 clinical images including rippled pretibial papules, interscapular macular amyloidosis, and full Congo red histology panel
- Systemic (AL) Amyloidosis — 4 images showing pinch purpura, raccoon-eye ecchymosis, macroglossia, and waxy papules
- Macular & Nodular Amyloidosis — differentiated from lichen type
Fully Illustrated With Clinical Photos:
| Category | Images |
|---|---|
| Amyloidosis (lichen + systemic) | ✅ 8 images |
| Bacterial infections (impetigo, furuncle, leprosy) | ✅ 10 images |
| Fungal infections (tinea, pityriasis versicolor, onychomycosis, candida) | ✅ 10 images |
| SJS/TEN/DRESS (drug reactions) | ✅ 5 images |
| Vasculitis / IgA vasculitis | ✅ 5 images |
| Mycosis fungoides / Kaposi sarcoma | ✅ 5 images |
| Epidermolysis bullosa | ✅ 4 images |
| Venereology (syphilis, herpes, STIs) | ✅ from previous session |
All Diseases Include:
- Clinical classification
- Diagnosis criteria
- Laboratory investigations
- Management approach
- Treatment (topical → systemic → biologic/advanced)
This is a shared conversation. Sign in to Orris to start your own chat.